08:00 , Nov 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Prohibitin 1 (PHB; PHB1) Nonhuman primate studies suggest a PHB1-binding...
08:00 , Nov 17, 2011 |  BC Innovations  |  Strategy

MD Anderson's private screening

Less than two years after The University of Texas MD Anderson Cancer Center carved up the IP for its in vivo phage display screening platform, the two biotech licensees have preclinical proof-of-concept data and preliminary...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Using in vivo phage selection to identify ligand-receptor pairs in blood vessels In vivo selection of phage display...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Arrowhead endocrine news

Arrowhead increased its stake in its Ablaris Therapeutics Inc. subsidiary to 64% from 55% after investing an additional $800,000 in the subsidiary in the second and final closing of a series A round. Ablaris raised...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Arrowhead, M.D. Anderson Cancer Center deal

The center granted Arrowhead an exclusive, worldwide license to technology related targeting the prohibitin 1 (PHB1) to treat weight-loss and obesity-related metabolic conditions. Arrowhead launched a new subsidiary, Ablaris Therapeutics Inc., to commercialize...